-+ 0.00%
-+ 0.00%
-+ 0.00%

Revolution Medicines Q3 2026 net loss widens 34% to $407.5 million

PUBT·11/04/2026 21:10:32
Listen to the news
Revolution Medicines Q3 2026 net loss widens 34% to $407.5 million
  • Revolution Medicines’ third-quarter 2026 net loss widened 34% year over year to $407.5 million.
  • RASONQUE net product revenue reached $197.6 million, reflecting approximately five weeks of commercial availability following U.S. FDA approval.
  • Research and development expenses rose 59% year over year to $417.1 million; selling, general and administrative expenses nearly tripled to $153.3 million.
  • A positive CHMP opinion recommended daraxonrasib’s approval for previously treated metastatic pancreatic cancer in the European Union.
  • Full-year 2026 GAAP operating expense guidance remained unchanged at $2.1 billion to $2.2 billion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revolution Medicines Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611041602PRIMZONEFULLFEED9870530) on November 04, 2026, and is solely responsible for the information contained therein.